

WILSON SONSINI

Nguyen T. Pham

OF COUNSEL

Technology
Transactions

*Palo Alto
Los Angeles*

npham@wsgr.com
650-849-3266

FOCUS AREAS

Biotech
Life Sciences
Medical Devices
Technology Transactions

HIGHLIGHTS

- **Leading Life Sciences Representation**
Nguyen focuses on the life sciences industry, representing innovative and leading companies and notable venture capital investors.
- **Comprehensive Transactional Experience**
Nguyen represents her clients in their strategic and IP-based transactional matters, including transactions with major biopharmaceutical and medical device companies, leading investors, and internationally recognized public and private research universities and institutions.

EXPERIENCE

Nguyen Pham is Of Counsel in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. Nguyen advises life sciences and technology companies on legal and business issues associated with the development, manufacture, and commercialization of their products, services, and intellectual property assets. Her practice focuses on representing public and private companies, including start-ups, in complex partnering and licensing arrangements, mergers and acquisitions, spin-outs, collaboration agreements, license agreements with academic and nonprofit institutions, research and development agreements, clinical trial agreements, and manufacturing, supply, and distribution agreements.

CREDENTIALS

Education

- J.D., UCLA School of Law
Chief Articles Editor, UCLA Journal of Law and Technology
- B.A., Human Biology, Stanford University
Minor in Modern Languages

Admissions

- State Bar of California

MATTERS

Representative Matters

- ABL Bio in its exclusive collaboration and worldwide license agreements with SANOFI and GSK
- Applied Molecular Transport in its \$177 million IPO

- Aytu BioPharma in its exclusive collaboration, distribution, and supply agreement with Lupin Pharma Canada Ltd
- Cyrano Therapeutics on its option agreement with KYORIN Pharmaceuticals for CYR-064, a novel treatment for hyposmia
- Distributed Bio in its acquisition by Charles River Laboratories
- Durect in the sale of its ALZET osmotic pump product line to Lafayette Instrument Company
- Novo Holdings in its Series A investments in Newleos Therapeutics and Reunion Neuroscience
- Parvus Therapeutics in its collaboration with Roche/Genentech for its tolerogenic nanoparticle products
- Qinotto in a research collaboration and license agreement with Eli Lilly
- Ripple Therapeutics in its collaboration and option-to-license agreement with AbbVie
- Vertos Medical in its acquisition by Stryker
- WuXi AppTec in its acquisition of OXGENE
- Multiple private biotechnology companies in collaboration and license agreements with major pharmaceutical companies including Eli Lilly and Novartis
- A private biopharmaceutical company in a spin-out from Gilead Sciences
- A contract development and manufacturing organization in a partnership with BioNTech for cell therapy products
- A private biotechnology company in a collaboration with Celltrion for COVID-19 therapies